<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Drug Development Consultant &#38; Regulatory Consultant &#187; EWG</title>
	<atom:link href="http://www.damienbove.com/tag/ewg/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.damienbove.com</link>
	<description>Damien Bove Shares The Expertise</description>
	<lastBuildDate>Thu, 09 Feb 2012 13:41:16 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>FDA Puiblish Guidance on Q4B, Evaluation and Recommendation of Pharmacopoeial Text for Use in ICH regions, Annex 12 Analytical Sieving General Chapter</title>
		<link>http://www.damienbove.com/2010/09/23/fda-puiblish-guidance-on-q4b-evaluation-and-recommendation-of-pharmacopoeial-text-for-use-in-ich-regions-annex-12-analytical-sieving-general-chapter/</link>
		<comments>http://www.damienbove.com/2010/09/23/fda-puiblish-guidance-on-q4b-evaluation-and-recommendation-of-pharmacopoeial-text-for-use-in-ich-regions-annex-12-analytical-sieving-general-chapter/#comments</comments>
		<pubDate>Thu, 23 Sep 2010 11:45:58 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Analytical sieving]]></category>
		<category><![CDATA[EWG]]></category>
		<category><![CDATA[ICH]]></category>
		<category><![CDATA[Pharmacopoeial]]></category>

		<guid isPermaLink="false">http://www.damienbove.com/?p=1853</guid>
		<description><![CDATA[This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions.  <a href="http://www.damienbove.com/2010/09/23/fda-puiblish-guidance-on-q4b-evaluation-and-recommendation-of-pharmacopoeial-text-for-use-in-ich-regions-annex-12-analytical-sieving-general-chapter/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<h1>FDA Publish Guidance on Q4B, Evaluation and Recommendation of Pharmacopoeial Text for Use in ICH regions, Annex 12 Analytical Sieving General Chapter.</h1>
<p>Full Text <a title="FDA Guidance" href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194492.pdf" target="_blank">Here</a></p>
<p>This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions. Implementation of the Q4B annexes is intended to avoid redundant testing by industry. For general information on the Q4B process, the reader is referred to the core guidance Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions.3<br />
This annex is the result of the Q4B process for the Analytical Sieving General Chapter. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).</p>
<h2>For access to a <a title="CMC Consultancy" href="http://www.damienbove.com/drug-development-and-planning-services/pharma-biotech-intellectual-property-cmc-services/" target="_blank">CMC Expert</a> Click Here</h2>
<p>Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.</p>
<h1>Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!</h1>
<p><!-- VZAAR START --></p>
<div class="vzaar_media_player"><object id="video" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="462" height="266" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="data" value="http://view.vzaar.com/314932.flashplayer" /><param name="allowScriptAccess" value="always" /><param name="allowFullScreen" value="true" /><param name="wmode" value="transparent" /><param name="flashvars" value="endText=Don%27t+forget+to+sign+up+for+our+FREE+regulatory+watch+newsletter%21&amp;colourSet=orange&amp;endLink=www.damienbove.com&amp;brandText=IDA+Consultants+-+Damien+Bove&amp;autoplay=true&amp;brandLink=www.damienbove.com" /><param name="src" value="http://view.vzaar.com/314932.flashplayer" /><param name="allowfullscreen" value="true" /><embed id="video" type="application/x-shockwave-flash" width="462" height="266" src="http://view.vzaar.com/314932.flashplayer" flashvars="endText=Don%27t+forget+to+sign+up+for+our+FREE+regulatory+watch+newsletter%21&amp;colourSet=orange&amp;endLink=www.damienbove.com&amp;brandText=IDA+Consultants+-+Damien+Bove&amp;autoplay=true&amp;brandLink=www.damienbove.com" wmode="transparent" allowfullscreen="true" allowscriptaccess="always" data="http://view.vzaar.com/314932.flashplayer"></embed></object></div>
<p><!-- VZAAR END --></p>
<p>Sign up for the most value add free newsource you can get for free.  We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between <em>20 and 40 new regulations, rules and initiatives each month</em>, and summaries them in a fantastic <strong>FREE monthly Regulatory and Market Round Up</strong>. You can Un-Subscribe at any time and we don not share your details with anybody. You can&#8217;t afford to miss out on this service. <em>Just fill in the form below</em>.</p>
<form action="http://www.damienbove.com/cgi-bin/arp3/arp3-formcapture.pl" method="POST">
<div>
<p>First name</p>
<input name="first_name" size="20" type="text" />
</div>
<div>
<p>Phone #1</p>
<input name="phone1" size="20" type="text" />
</div>
<div>
<p>E-mail address</p>
<input name="email" size="20" type="text" />
</div>
<input name="subscription_type" type="hidden" value="E" />
<div>
<input type="submit" value="Yes Please Sign Me Up »" /></div>
<input name="id" type="hidden" value="7" />
<input name="extra_ar" type="hidden" value="|2" />
</form>
<p><em>“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”</em></p>
]]></content:encoded>
			<wfw:commentRss>http://www.damienbove.com/2010/09/23/fda-puiblish-guidance-on-q4b-evaluation-and-recommendation-of-pharmacopoeial-text-for-use-in-ich-regions-annex-12-analytical-sieving-general-chapter/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Publish Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in ICH regions, Annex 11, Capillary Electrophoresis General Chapter</title>
		<link>http://www.damienbove.com/2010/09/22/fda-publish-q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-ich-regions-annex-11-capillary-electrophoresis-general-chapter/</link>
		<comments>http://www.damienbove.com/2010/09/22/fda-publish-q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-ich-regions-annex-11-capillary-electrophoresis-general-chapter/#comments</comments>
		<pubDate>Wed, 22 Sep 2010 11:41:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[capillary electrophoresis]]></category>
		<category><![CDATA[EWG]]></category>
		<category><![CDATA[ICH]]></category>
		<category><![CDATA[Q4B]]></category>

		<guid isPermaLink="false">http://www.damienbove.com/?p=1851</guid>
		<description><![CDATA[This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions.  <a href="http://www.damienbove.com/2010/09/22/fda-publish-q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-ich-regions-annex-11-capillary-electrophoresis-general-chapter/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<h1>FDA Publish Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in ICH regions, Annex 11, Capillary Electrophoresis General Chapter.</h1>
<p>Full Text <a title="FDA Guidance" href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194492.pdf " target="_blank">Here</a></p>
<p>This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions. Implementation of the Q4B annexes is intended to avoid redundant testing by industry. For general information on the Q4B process, the reader is referred to the core guidance Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions.<br />
This annex is the result of the Q4B process for the Capillary Electrophoresis General Chapter. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).</p>
<h2>For A <a title="CMC Consultancy" href="http://www.damienbove.com/drug-development-and-planning-services/pharma-biotech-intellectual-property-cmc-services/" target="_self">CMC Expert</a> Click Here</h2>
<p>Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.</p>
<h1>Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!</h1>
<p><!-- VZAAR START --></p>
<div class="vzaar_media_player"><object id="video" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="462" height="266" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="data" value="http://view.vzaar.com/314932.flashplayer" /><param name="allowScriptAccess" value="always" /><param name="allowFullScreen" value="true" /><param name="wmode" value="transparent" /><param name="flashvars" value="endText=Don%27t+forget+to+sign+up+for+our+FREE+regulatory+watch+newsletter%21&amp;colourSet=orange&amp;endLink=www.damienbove.com&amp;brandText=IDA+Consultants+-+Damien+Bove&amp;autoplay=true&amp;brandLink=www.damienbove.com" /><param name="src" value="http://view.vzaar.com/314932.flashplayer" /><param name="allowfullscreen" value="true" /><embed id="video" type="application/x-shockwave-flash" width="462" height="266" src="http://view.vzaar.com/314932.flashplayer" flashvars="endText=Don%27t+forget+to+sign+up+for+our+FREE+regulatory+watch+newsletter%21&amp;colourSet=orange&amp;endLink=www.damienbove.com&amp;brandText=IDA+Consultants+-+Damien+Bove&amp;autoplay=true&amp;brandLink=www.damienbove.com" wmode="transparent" allowfullscreen="true" allowscriptaccess="always" data="http://view.vzaar.com/314932.flashplayer"></embed></object></div>
<p><!-- VZAAR END --></p>
<p>Sign up for the most value add free newsource you can get for free.  We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between <em>20 and 40 new regulations, rules and initiatives each month</em>, and summaries them in a fantastic <strong>FREE monthly Regulatory and Market Round Up</strong>. You can Un-Subscribe at any time and we don not share your details with anybody. You can&#8217;t afford to miss out on this service. <em>Just fill in the form below</em>.</p>
<form action="http://www.damienbove.com/cgi-bin/arp3/arp3-formcapture.pl" method="POST">
<div>
<p>First name</p>
<input name="first_name" size="20" type="text" />
</div>
<div>
<p>Phone #1</p>
<input name="phone1" size="20" type="text" />
</div>
<div>
<p>E-mail address</p>
<input name="email" size="20" type="text" />
</div>
<input name="subscription_type" type="hidden" value="E" />
<div>
<input type="submit" value="Yes Please Sign Me Up »" /></div>
<input name="id" type="hidden" value="7" />
<input name="extra_ar" type="hidden" value="|2" />
</form>
<p><em>“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”</em></p>
]]></content:encoded>
			<wfw:commentRss>http://www.damienbove.com/2010/09/22/fda-publish-q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-ich-regions-annex-11-capillary-electrophoresis-general-chapter/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Regulators, FDA CDER, Publish Guidance on ICH Q4B Annex 10 Polyacrylamide Gel Electrophoresis General Chapter for Pharmacopoeial Texts</title>
		<link>http://www.damienbove.com/2010/05/06/drug-regulators-fda-cder-publish-guidance-on-ich-q4b-annex-10-polyacrylamide-gel-electrophoresis-general-chapter-for-pharmacopoeial-texts/</link>
		<comments>http://www.damienbove.com/2010/05/06/drug-regulators-fda-cder-publish-guidance-on-ich-q4b-annex-10-polyacrylamide-gel-electrophoresis-general-chapter-for-pharmacopoeial-texts/#comments</comments>
		<pubDate>Thu, 06 May 2010 06:45:50 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[EWG]]></category>
		<category><![CDATA[expert working group]]></category>
		<category><![CDATA[ICH]]></category>
		<category><![CDATA[pharmacopeial]]></category>
		<category><![CDATA[polyacrylamide Gel Electrophoresis]]></category>
		<category><![CDATA[Q4B]]></category>

		<guid isPermaLink="false">http://www.damienbove.com/?p=1327</guid>
		<description><![CDATA[This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions <a href="http://www.damienbove.com/2010/05/06/drug-regulators-fda-cder-publish-guidance-on-ich-q4b-annex-10-polyacrylamide-gel-electrophoresis-general-chapter-for-pharmacopoeial-texts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<h1>Drug Regulators, FDA CDER, Publish Guidance on ICH Q4B Annex 10 Polyacrylamide Gel Electrophoresis General Chapter for Pharmacopoeial Texts</h1>
<p>Full Text <a title="FDA CDER Guidance" href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM176889.pdf " target="_blank">Here</a></p>
<p>This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions. Implementation of the Q4B annexes is intended to avoid redundant testing by industry. For general information on the Q4B process, the reader is referred to the core guidance Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions.</p>
<p>This annex is the result of the Q4B process for the Polyacrylamide Gel Electrophoresis General Chapter. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).</p>
<h2><a title="CMC Consultancy Services" href="http://www.damienbove.com/drug-development-and-planning-services/pharma-biotech-intellectual-property-cmc-services/" target="_blank">Click Here &#8211; CMC Consulting Services &#8211; Click Here</a></h2>
<p>Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.</p>
<h1>Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!</h1>
<p>Sign up for the most value add free newsource you can get for free.  We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between <em>20 and 40 new regulations, rules and initiatives each month</em>, and summaries them in a fantastic <strong>FREE monthly Regulatory and Market Round Up</strong>. You can Un-Subscribe at any time and we don not share your details with anybody. You can&#8217;t afford to miss out on this service. <em>Just fill in the form below</em>.</p>
<form action="http://www.damienbove.com/cgi-bin/arp3/arp3-formcapture.pl" method="POST">
<div>
<p>First name</p>
<input name="first_name" size="20" type="text" />
</div>
<div>
<p>Phone #1</p>
<input name="phone1" size="20" type="text" />
</div>
<div>
<p>E-mail address</p>
<input name="email" size="20" type="text" />
</div>
<input name="subscription_type" type="hidden" value="E" />
<div>
<input type="submit" value="Yes Please, Sign Me Up!" /></div>
<input name="id" type="hidden" value="7" />
<div id="attachment_191" class="wp-caption aligncenter" style="width: 525px"><a href="http://www.damienbove.com/free-strategic-review/"><img class="size-full wp-image-191" title="Free Strategy Consultation - Biotech Pharma Regualtory" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/04/ida_consultants_freestrategyconsultation_515x64.jpg" alt="ida consultants freestrategyconsultation 515x64 Drug Regulators, FDA CDER, Publish Guidance on ICH Q4B Annex 10 Polyacrylamide Gel Electrophoresis General Chapter for Pharmacopoeial Texts" width="515" height="64" /></a><p class="wp-caption-text">Free Strategy Consultation - Biotech Pharma Regualtory</p></div>
<input name="extra_ar" type="hidden" value="|2" />
</form>
<p><em>“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”</em></p>
<p><em><a href="http://www.damienbove.com/how-to-write-a-business-plan/"><img class="aligncenter size-full wp-image-640" title="How To Write A Business Plan" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/07/ida_100programme_515x64_LowRes.jpg" alt="ida 100programme 515x64 LowRes Drug Regulators, FDA CDER, Publish Guidance on ICH Q4B Annex 10 Polyacrylamide Gel Electrophoresis General Chapter for Pharmacopoeial Texts" width="515" height="64" /></a><br />
</em></p>
]]></content:encoded>
			<wfw:commentRss>http://www.damienbove.com/2010/05/06/drug-regulators-fda-cder-publish-guidance-on-ich-q4b-annex-10-polyacrylamide-gel-electrophoresis-general-chapter-for-pharmacopoeial-texts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Regulators, FDA, CDER, Publish Guidance on ICH Q4B Annex 7 Dissolution Tests General Chapter for Pharmacopoeial Texts</title>
		<link>http://www.damienbove.com/2010/05/05/drug-regulators-fda-cder-publish-guidance-on-ich-q4b-annex-7-dissolution-tests-general-chapter-for-pharmacopoeial-texts/</link>
		<comments>http://www.damienbove.com/2010/05/05/drug-regulators-fda-cder-publish-guidance-on-ich-q4b-annex-7-dissolution-tests-general-chapter-for-pharmacopoeial-texts/#comments</comments>
		<pubDate>Wed, 05 May 2010 06:41:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[disolution testing]]></category>
		<category><![CDATA[EWG]]></category>
		<category><![CDATA[expert working group]]></category>
		<category><![CDATA[ICH]]></category>
		<category><![CDATA[pharmacopeial]]></category>
		<category><![CDATA[Q4B]]></category>

		<guid isPermaLink="false">http://www.damienbove.com/?p=1325</guid>
		<description><![CDATA[his annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions <a href="http://www.damienbove.com/2010/05/05/drug-regulators-fda-cder-publish-guidance-on-ich-q4b-annex-7-dissolution-tests-general-chapter-for-pharmacopoeial-texts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<h1>Drug Regulators, FDA, CDER, Publish Guidance on ICH Q4B Annex 7 Dissolution Tests General Chapter for Pharmacopoeial Texts</h1>
<p>full text <a title="FDA CDER Guidance" href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm085366.pdf " target="_blank">here</a></p>
<p>This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions. Implementation of the Q4B annexes is intended to avoid redundant testing by industry. For general information on the Q4B process, the reader is referred to the core guidance Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions.<br />
This annex is the result of the Q4B process for the Dissolution Test General Chapter. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).</p>
<h2><a title="CMC Consulting Services" href="http://www.damienbove.com/drug-development-and-planning-services/pharma-biotech-intellectual-property-cmc-services/" target="_blank">Click Here &#8211; CMC Consulting Services &#8211; Click Here</a></h2>
<p>Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.</p>
<h1>Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!</h1>
<p>Sign up for the most value add free newsource you can get for free.  We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between <em>20 and 40 new regulations, rules and initiatives each month</em>, and summaries them in a fantastic <strong>FREE monthly Regulatory and Market Round Up</strong>. You can Un-Subscribe at any time and we don not share your details with anybody. You can&#8217;t afford to miss out on this service. <em>Just fill in the form below</em>.</p>
<form action="http://www.damienbove.com/cgi-bin/arp3/arp3-formcapture.pl" method="POST">
<div>
<p>First name</p>
<input name="first_name" size="20" type="text" />
</div>
<div>
<p>Phone #1</p>
<input name="phone1" size="20" type="text" />
</div>
<div>
<p>E-mail address</p>
<input name="email" size="20" type="text" />
</div>
<input name="subscription_type" type="hidden" value="E" />
<div>
<input type="submit" value="Yes Please, Sign Me Up!" /></div>
<input name="id" type="hidden" value="7" />
<div id="attachment_191" class="wp-caption aligncenter" style="width: 525px"><a href="http://www.damienbove.com/free-strategic-review/"><img class="size-full wp-image-191" title="Free Strategy Consultation - Biotech Pharma Regualtory" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/04/ida_consultants_freestrategyconsultation_515x64.jpg" alt="ida consultants freestrategyconsultation 515x64 Drug Regulators, FDA, CDER, Publish Guidance on ICH Q4B Annex 7 Dissolution Tests General Chapter for Pharmacopoeial Texts" width="515" height="64" /></a><p class="wp-caption-text">Free Strategy Consultation - Biotech Pharma Regualtory</p></div>
<input name="extra_ar" type="hidden" value="|2" />
</form>
<p><em>“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”</em></p>
<p><em><a href="http://www.damienbove.com/how-to-write-a-business-plan/"><img class="aligncenter size-full wp-image-640" title="How To Write A Business Plan" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/07/ida_100programme_515x64_LowRes.jpg" alt="ida 100programme 515x64 LowRes Drug Regulators, FDA, CDER, Publish Guidance on ICH Q4B Annex 7 Dissolution Tests General Chapter for Pharmacopoeial Texts" width="515" height="64" /></a><br />
</em></p>
]]></content:encoded>
			<wfw:commentRss>http://www.damienbove.com/2010/05/05/drug-regulators-fda-cder-publish-guidance-on-ich-q4b-annex-7-dissolution-tests-general-chapter-for-pharmacopoeial-texts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Regulators, FDA, CDER, Publish Guidance on ICH Tablet Friability Q4B Annex 9</title>
		<link>http://www.damienbove.com/2010/05/04/drug-regulators-fda-cder-publish-guidance-on-ich-tablet-friability-q4b-annex-9/</link>
		<comments>http://www.damienbove.com/2010/05/04/drug-regulators-fda-cder-publish-guidance-on-ich-tablet-friability-q4b-annex-9/#comments</comments>
		<pubDate>Tue, 04 May 2010 06:40:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[EWG]]></category>
		<category><![CDATA[expert working group]]></category>
		<category><![CDATA[ICH]]></category>
		<category><![CDATA[pharmacopeial]]></category>
		<category><![CDATA[Q4B]]></category>
		<category><![CDATA[Tablet Friability]]></category>

		<guid isPermaLink="false">http://www.damienbove.com/?p=1323</guid>
		<description><![CDATA[This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions <a href="http://www.damienbove.com/2010/05/04/drug-regulators-fda-cder-publish-guidance-on-ich-tablet-friability-q4b-annex-9/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<h1>Drug Regulators, FDA, CDER, Publish Guidance on ICH Tablet Friability Q4B Annex 9</h1>
<p>Full Text <a title="FDA CDER Guidance" href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM176888.pdf " target="_blank">Hear</a></p>
<p>This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions. Implementation of the Q4B annexes is intended to avoid redundant testing by industry. For general information on the Q4B process, the reader is referred to the core guidance Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions.</p>
<p>This annex is the result of the Q4B process for the Tablet Friability General Chapter. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).</p>
<h2><a title="CMC Consultancy Services" href="http://www.damienbove.com/drug-development-and-planning-services/pharma-biotech-intellectual-property-cmc-services/" target="_self">Click Here &#8211; CMC Consulting Services &#8211; Click Here</a></h2>
<p>Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.</p>
<h1>Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!</h1>
<p>Sign up for the most value add free newsource you can get for free.  We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between <em>20 and 40 new regulations, rules and initiatives each month</em>, and summaries them in a fantastic <strong>FREE monthly Regulatory and Market Round Up</strong>. You can Un-Subscribe at any time and we don not share your details with anybody. You can&#8217;t afford to miss out on this service. <em>Just fill in the form below</em>.</p>
<form action="http://www.damienbove.com/cgi-bin/arp3/arp3-formcapture.pl" method="POST">
<div>
<p>First name</p>
<input name="first_name" size="20" type="text" />
</div>
<div>
<p>Phone #1</p>
<input name="phone1" size="20" type="text" />
</div>
<div>
<p>E-mail address</p>
<input name="email" size="20" type="text" />
</div>
<input name="subscription_type" type="hidden" value="E" />
<div>
<input type="submit" value="Yes Please, Sign Me Up!" /></div>
<input name="id" type="hidden" value="7" />
<div id="attachment_191" class="wp-caption aligncenter" style="width: 525px"><a href="http://www.damienbove.com/free-strategic-review/"><img class="size-full wp-image-191" title="Free Strategy Consultation - Biotech Pharma Regualtory" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/04/ida_consultants_freestrategyconsultation_515x64.jpg" alt="ida consultants freestrategyconsultation 515x64 Drug Regulators, FDA, CDER, Publish Guidance on ICH Tablet Friability Q4B Annex 9" width="515" height="64" /></a><p class="wp-caption-text">Free Strategy Consultation - Biotech Pharma Regualtory</p></div>
<input name="extra_ar" type="hidden" value="|2" />
</form>
<p><em>“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”</em></p>
<p><em><a href="http://www.damienbove.com/how-to-write-a-business-plan/"><img class="aligncenter size-full wp-image-640" title="How To Write A Business Plan" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/07/ida_100programme_515x64_LowRes.jpg" alt="ida 100programme 515x64 LowRes Drug Regulators, FDA, CDER, Publish Guidance on ICH Tablet Friability Q4B Annex 9" width="515" height="64" /></a><br />
</em></p>
]]></content:encoded>
			<wfw:commentRss>http://www.damienbove.com/2010/05/04/drug-regulators-fda-cder-publish-guidance-on-ich-tablet-friability-q4b-annex-9/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Regulators, FDA CDER, Publish Guidance on Q4B Annex 8 Sterility Test General Chapter for ICH Regions</title>
		<link>http://www.damienbove.com/2010/01/08/drug-regulators-fda-cder-publish-guidance-on-q4b-annex-8-sterility-test-general-chapter-for-ich-regions/</link>
		<comments>http://www.damienbove.com/2010/01/08/drug-regulators-fda-cder-publish-guidance-on-q4b-annex-8-sterility-test-general-chapter-for-ich-regions/#comments</comments>
		<pubDate>Fri, 08 Jan 2010 07:35:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[EWG]]></category>
		<category><![CDATA[ICH]]></category>
		<category><![CDATA[PDG]]></category>
		<category><![CDATA[Pharmacopeil Discussion Group]]></category>
		<category><![CDATA[Q4B]]></category>
		<category><![CDATA[Sterility]]></category>

		<guid isPermaLink="false">http://www.damienbove.com/?p=1097</guid>
		<description><![CDATA[This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions. <a href="http://www.damienbove.com/2010/01/08/drug-regulators-fda-cder-publish-guidance-on-q4b-annex-8-sterility-test-general-chapter-for-ich-regions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<h1>Drug Regulators, FDA CDER, Publish Guidance on Q4B Annex 8 Sterility Test General Chapter for ICH Regions</h1>
<p>Full Text <a title="FDA CDER Guidance" href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm085370.pdf " target="_blank">Here</a></p>
<p>This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions. Implementation of the Q4B annexes is intended to avoid redundant testing by industry. For general information on the Q4B process, the reader is referred to the core guidance Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions.<br />
This annex is the result of the Q4B process for the Sterility Test General Chapter. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).</p>
<p>Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug  development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.</p>
<h1><strong>Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free.<br />
</strong></h1>
<p><span style="font-weight: normal; font-size: 13px;">As you know this website is a great resource for keeping up to date with developments and regulations, why not get our </span><span style="font-size: 13px;"><strong>FREE</strong></span><span style="font-weight: normal; font-size: 13px;"><strong> monthly regulatory and market round up</strong></span><span style="font-weight: normal; font-size: 13px;">. You can un-subscribe at any time and we do not share your details with anybody.</span></p>
<form action="http://www.damienbove.com/cgi-bin/arp3/arp3-formcapture.pl" method="POST">
<div>
<p>First name</p>
<input name="first_name" size="20" type="text" />
</div>
<div>
<p>E-mail address</p>
<input name="email" size="20" type="text" />
</div>
<input name="subscription_type" type="hidden" value="E" />
<div>
<input type="submit" value="Go »" /></div>
<input name="id" type="hidden" value="2" />
<input name="extra_ar" type="hidden" />
</form>
<div id="_mcePaste" style="overflow: hidden; position: absolute; left: -10000px; top: 0px; width: 1px; height: 1px;">This guideline ap</div>
<div id="_mcePaste" style="overflow: hidden; position: absolute; left: -10000px; top: 0px; width: 1px; height: 1px;">recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.</div>
<dl id="attachment_191" class="wp-caption aligncenter" style="display: block; margin-left: auto; margin-right: auto; text-align: center; background-color: #f3f3f3; padding-top: 4px; margin-top: 10px; margin-bottom: 10px; -webkit-border-top-right-radius: 3px 3px; -webkit-border-top-left-radius: 3px 3px; -webkit-border-bottom-left-radius: 3px 3px; -webkit-border-bottom-right-radius: 3px 3px; border: 1px solid #dddddd;">
<dt class="wp-caption-dt"><a href="http://www.damienbove.com/?page_id=183"><img class="size-full wp-image-191" style="padding: 0px; margin: 0px; border: 0px none initial;" title="Free Strategy Consultation - Biotech Pharma Regualtory" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/04/ida_consultants_freestrategyconsultation_515x64.jpg" alt="ida consultants freestrategyconsultation 515x64 Drug Regulators, FDA CDER, Publish Guidance on Q4B Annex 8 Sterility Test General Chapter for ICH Regions" width="515" height="64" /></a></dt>
</dl>
<p><!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves /> <w:TrackFormatting /> <w:PunctuationKerning /> <w:ValidateAgainstSchemas /> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF /> <w:LidThemeOther>EN-GB</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables /> <w:SnapToGridInCell /> <w:WrapTextWithPunct /> <w:UseAsianBreakRules /> <w:DontGrowAutofit /> <w:SplitPgBreakAndParaMark /> <w:DontVertAlignCellWithSp /> <w:DontBreakConstrainedForcedTables /> <w:DontVertAlignInTxbx /> <w:Word11KerningPairs /> <w:CachedColBalance /> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> <m:mathPr> <m:mathFont m:val="Cambria Math" /> <m:brkBin m:val="before" /> <m:brkBinSub m:val="&#45;-" /> <m:smallFrac m:val="off" /> <m:dispDef /> <m:lMargin m:val="0" /> <m:rMargin m:val="0" /> <m:defJc m:val="centerGroup" /> <m:wrapIndent m:val="1440" /> <m:intLim m:val="subSup" /> <m:naryLim m:val="undOvr" /> </m:mathPr></w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"   DefSemiHidden="true" DefQFormat="false" DefPriority="99"   LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Normal" /> <w:LsdException Locked="false" Priority="9" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="heading 1" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9" /> <w:LsdException Locked="false" Priority="39" Name="toc 1" /> <w:LsdException Locked="false" Priority="39" Name="toc 2" /> <w:LsdException Locked="false" Priority="39" Name="toc 3" /> <w:LsdException Locked="false" Priority="39" Name="toc 4" /> <w:LsdException Locked="false" Priority="39" Name="toc 5" /> <w:LsdException Locked="false" Priority="39" Name="toc 6" /> <w:LsdException Locked="false" Priority="39" Name="toc 7" /> <w:LsdException Locked="false" Priority="39" Name="toc 8" /> <w:LsdException Locked="false" Priority="39" Name="toc 9" /> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption" /> <w:LsdException Locked="false" Priority="10" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Title" /> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font" /> <w:LsdException Locked="false" Priority="11" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtitle" /> <w:LsdException Locked="false" Priority="22" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Strong" /> <w:LsdException Locked="false" Priority="20" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Emphasis" /> <w:LsdException Locked="false" Priority="59" SemiHidden="false"    UnhideWhenUsed="false" Name="Table Grid" /> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text" /> <w:LsdException Locked="false" Priority="1" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="No Spacing" /> <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading" /> <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List" /> <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid" /> <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1" /> <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2" /> <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1" /> <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2" /> <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1" /> <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2" /> <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3" /> <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List" /> <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading" /> <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List" /> <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid" /> <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 1" /> <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 1" /> <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 1" /> <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1" /> <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1" /> <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 1" /> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision" /> <w:LsdException Locked="false" Priority="34" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="List Paragraph" /> <w:LsdException Locked="false" Priority="29" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Quote" /> <w:LsdException Locked="false" Priority="30" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Quote" /> <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 1" /> <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1" /> <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1" /> <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1" /> <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 1" /> <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 1" /> <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 1" /> <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 1" /> <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 2" /> <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 2" /> <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 2" /> <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2" /> <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2" /> <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 2" /> <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 2" /> <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2" /> <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2" /> <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2" /> <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 2" /> <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 2" /> <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 2" /> <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 2" /> <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 3" /> <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 3" /> <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 3" /> <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3" /> <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3" /> <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 3" /> <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 3" /> <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3" /> <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3" /> <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3" /> <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 3" /> <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 3" /> <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 3" /> <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 3" /> <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 4" /> <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 4" /> <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 4" /> <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4" /> <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4" /> <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 4" /> <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 4" /> <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4" /> <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4" /> <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4" /> <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 4" /> <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 4" /> <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 4" /> <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 4" /> <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 5" /> <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 5" /> <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 5" /> <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5" /> <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5" /> <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 5" /> <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 5" /> <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5" /> <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5" /> <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5" /> <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 5" /> <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 5" /> <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 5" /> <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 5" /> <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 6" /> <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 6" /> <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 6" /> <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6" /> <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6" /> <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 6" /> <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 6" /> <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6" /> <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6" /> <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6" /> <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 6" /> <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 6" /> <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 6" /> <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 6" /> <w:LsdException Locked="false" Priority="19" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis" /> <w:LsdException Locked="false" Priority="21" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis" /> <w:LsdException Locked="false" Priority="31" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference" /> <w:LsdException Locked="false" Priority="32" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Reference" /> <w:LsdException Locked="false" Priority="33" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Book Title" /> <w:LsdException Locked="false" Priority="37" Name="Bibliography" /> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading" /> </w:LatentStyles> </xml><![endif]--> <!--[if gte mso 10]> <mce:style><! /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} --> <!--[endif]--></p>
<p class="22-Modeltext" style="margin-bottom: 0.0001pt;">
<p style="text-align: center;"><a title="How To Write a Business Plan" href="http://www.damienbove.com/how-to-write-a-business-plan/"><img class="size-full wp-image-640 aligncenter" title="How To Write A Business Plan" src="http://www.damienbove.com/wordpress/wp-content/uploads/2009/07/ida_100programme_515x64_LowRes.jpg" alt="ida 100programme 515x64 LowRes Drug Regulators, FDA CDER, Publish Guidance on Q4B Annex 8 Sterility Test General Chapter for ICH Regions" width="489" height="61" /></a></p>
<h1 style="text-align: left;">Turn your Business Into an Investor Magnet</h1>
<h2 style="text-align: left;">How to Write a Business Plan &#8211; Free E-Course</h2>
<p>Get the secrets that turns your project into an investment magnet, <strong>100% of our clients raise the finance they need to take their projects to the next stage</strong>, we will share these secrets with you. &#8211; <a title="How To Write a Business Plan" href="http://www.damienbove.com/how-to-write-a-business-plan/" target="_self">Sign up for Free</a></p>
<p class="22-Modeltext" style="margin-bottom: 0.0001pt;"><em><span style="font-family: &amp;amp;quot;">“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”<span> </span></span></em></p>
]]></content:encoded>
			<wfw:commentRss>http://www.damienbove.com/2010/01/08/drug-regulators-fda-cder-publish-guidance-on-q4b-annex-8-sterility-test-general-chapter-for-ich-regions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

